Nanjing Vazyme Biotech Co Ltd (688105) fair value: what the stock is really worth
As of Nov 12, 2026: fair value (intrinsic value) of Nanjing Vazyme Biotech Co Ltd stock ¥7.46, price ¥22.85, that is 67.3% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range ¥12.50 – ¥87.89 · fair‑value band ¥4.83 – ¥12.15 · the ¥22.85 price screens above the ¥7.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 12, 2026.
Follow Nanjing Vazyme Biotech Co in your weekly email
Every Wednesday you see whether Nanjing Vazyme Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics.
Show moreShow less
The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and cell and protein research reagents.
It also provides NGS library preparation reagents, such as DNA sequencing, RNA sequencing, target capture sequencing, epigenetics, magnetic beads, NGS library quantification, and single-cell sequencing; reagents for biomedicine, including mRNA vaccine/drug key components, drug discovery tools, ELISA kits vaccine evaluation reagents, and semaglutide drug key components; instruments, including automated liquid handling workstation, automatic nucleic acid isolation system, real-time fluorescence quantitative PCR system, fluorescence quantimeter, and micro horizontal centrifuge; lab consumables for equipment comprising robotic pipette tips, robotic microwell plates, robotic deep well plates, and 96-well flat-bottom microplates; and monkeypox solutions.
The company was founded in 2012 and is headquartered in Nanjing, China.
Stock analysis
Nanjing Vazyme Biotech Co Ltd (688105) currently trades at ¥22.85, while our model-based Fair Value estimate is ¥7.46, 67% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥9.81 per share, and 0 of the 11 models we run sit above the ¥22.85 price.
Bear case: the Multiples group reads lowest at ¥3.32, and 11 of the 11 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥4.83 (bear) to ¥12.15 (bull), the price of ¥22.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Nanjing Vazyme Biotech Co Ltd reported revenue of 1.4B CNY in FY2025 versus 1.9B CNY in FY2021, a compound −7.3%/yr. Reported net income was −17.0M CNY in FY2025.
Key figures
Market cap 10.6B CNY (≈ $1.6B) Small · P/S ratio 7.21 · EPS (TTM) ¥−0.0100 · Dividend yield 1.7% · Net margin −0.6% · Return on equity −0.5% · Return on assets (EBIT) 5.0% (5-year average) · Operating margin −5.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 74% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −67%, 688105 screens richer than that median.
Fair Value models
Bear¥4.83Fair Value ¥7.46Bull¥12.15
Price ¥22.85 · Downside -67.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥7.02¥9.57¥17.1976
Growth DCF¥6.68¥10.10¥16.4474
5Y EBITDA Exit¥4.81¥6.72¥10.3872
All 11 models by family
DCF Models
FCF DCF¥7.02¥9.57¥17.1976
Owner Earnings¥5.23¥9.20¥16.6371
5Y Revenue Exit¥5.68¥8.51¥14.3268
5Y EBITDA Exit¥4.81¥6.72¥10.3872
10Y Revenue Exit¥6.00¥10.47¥13.5464
10Y EBITDA Exit¥5.53¥8.78¥14.2964
Multiples
EV/EBITDA¥1.72¥2.46¥3.2064
EV/Revenue¥2.77¥4.17¥5.5751
Asset-Based
NCAV (Graham)¥3.16¥4.79¥5.9952
Growth DCF
Growth DCF¥6.68¥10.10¥16.4474
Rev-Margin DCF¥5.68¥9.52¥16.0768
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−27.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.8%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
62.2% (2020) → −2.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+14.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +24.5% a year for the price and +12.9% for the forecasts.
Compare Nanjing Vazyme Biotech Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score50 · Above median
Fair Value upside−67.3% · Bottom 25%
Profitability
Return on assets−0.3% · Top 25%
Net margin (12 months)−0.6% · Above median
Operating margin (12 months)−5.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)18.2% · Above median
Dividend yield (12 months)1.7% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.80× · Pricier than median
P/S (12 months)7.21× · Cheaper than median
Price / free cash flow (fiscal year)57.1× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)91· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 96
DIVIDEND (yield)34· sector 20
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nanjing Vazyme Biotech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/688105
Frequently asked questions
Is Nanjing Vazyme Biotech Co Ltd (688105) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ¥7.46 versus a price of ¥22.85, about 67% lower (overvalued).
What is the fair value of 688105?
Our model-based fair value for Nanjing Vazyme Biotech Co Ltd is ¥7.46 (as of Nov 12, 2026), built from audited fundamentals. The current price: ¥22.85.
What is the quality score of 688105?
Nanjing Vazyme Biotech Co Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nanjing Vazyme Biotech Co Ltd (688105)?
Our model-based price target is the fair value of ¥7.46 (as of Nov 12, 2026) from 11 valuation models. Cautious scenario ¥4.83, optimistic scenario ¥12.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Nanjing Vazyme Biotech Co Ltd stock forecast for 2026?
Our models put fair value at ¥7.46, about 67% lower versus a price of ¥22.85 (overvalued). Cautious scenario ¥4.83, optimistic scenario ¥12.15. The calculation is refreshed regularly with new filings.
What is the revenue of Nanjing Vazyme Biotech Co Ltd (688105)?
Nanjing Vazyme Biotech Co Ltd reported trailing-twelve-month revenue of about 1.5B CNY (latest available figure, as of Nov 12, 2026).
Does Nanjing Vazyme Biotech Co Ltd pay a dividend?
Nanjing Vazyme Biotech Co Ltd currently shows a dividend yield of 1.68% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Nanjing Vazyme Biotech Co Ltd (688105) and when is the ex-dividend date?
Nanjing Vazyme Biotech Co Ltd pays a dividend of ¥0.385 per share a year, a dividend yield of 1.7%. The last ex-dividend date was Jun 3, 2026. A dividend has been paid every year since at least 2022. Free cash flow covers the dividend 0.93 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Nanjing Vazyme Biotech Co Ltd (688105)?
For today's price to be fair in a discounted-cash-flow model, Nanjing Vazyme Biotech Co Ltd would have to grow free cash flow by +26.6 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.5 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of 688105 use?
Our models discount Nanjing Vazyme Biotech Co Ltd at 10.9 %: a base by market capitalisation (small), damped by beta 0.65, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nanjing Vazyme Biotech Co Ltd that is +26.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Nanjing Vazyme Biotech Co Ltd (688105) delivered so far?
Over the past 5 years revenue at Nanjing Vazyme Biotech Co Ltd grew -2.5 % a year. The price currently implies free-cash-flow growth of +26.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Nanjing Vazyme Biotech Co Ltd (688105) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Nanjing Vazyme Biotech Co Ltd (+26.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Nanjing Vazyme Biotech Co Ltd (688105)?
The free-cash-flow yield on the price is 1.92 %: that much free cash flow Nanjing Vazyme Biotech Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nanjing Vazyme Biotech Co Ltd (688105)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanjing Vazyme Biotech Co Ltd it is ¥7.46 per share (as of Nov 12, 2026), against a price of ¥22.85. It is the blended result of 11 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Nanjing Vazyme Biotech Co Ltd stock overvalued or undervalued in 2026?
As of Nov 12, 2026, 688105 trades above its calculated fair value: price ¥22.85, fair value ¥7.46, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688105?
No. The price is what the market pays today (¥22.85); the fair value is what the company's own numbers justify (¥7.46). For Nanjing Vazyme Biotech Co Ltd the two are ¥15.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nanjing Vazyme Biotech Co Ltd worth?
The market values Nanjing Vazyme Biotech Co Ltd at about 10.6B CNY (market capitalisation, as of Nov 12, 2026). Per share that is ¥22.85; our models calculate a fair value of ¥7.46 per share.
What do the bullish and bearish scenarios say about 688105?
Our models span a range for Nanjing Vazyme Biotech Co Ltd: cautious scenario ¥4.83, base ¥7.46, optimistic ¥12.15 per share (as of Nov 12, 2026, price ¥22.85). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nanjing Vazyme Biotech Co Ltd (688105)?
Balance-sheet figures for Nanjing Vazyme Biotech Co Ltd (as of Nov 12, 2026): return on equity −0.5%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 688105 from its 52-week high?
Nanjing Vazyme Biotech Co Ltd trades at ¥22.85, about 17% below its 52-week high of ¥27.59 and 74% above the low of ¥13.14 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.46 is for.
Which stocks are comparable to Nanjing Vazyme Biotech Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nanjing Vazyme Biotech Co Ltd stock attractive at the current price?
The data as of Nov 12, 2026: price ¥22.85, calculated fair value ¥7.46 (−67%), Quality Score 50/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688105 calculated?
We run Nanjing Vazyme Biotech Co Ltd through 11 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of ¥7.46 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Nanjing Vazyme Biotech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nanjing Vazyme Biotech Co Ltd (688105)?
The closing price on Nov 12, 2026 was ¥22.85. Our model-based fair value is ¥7.46, about 67% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nanjing Vazyme Biotech Co Ltd right now?
The price sits above even our optimistic bull case (¥12.15). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥4.83 to ¥12.15) leaves room in how you read the outcome.
Key figures of Nanjing Vazyme Biotech Co Ltd
How large is the market capitalisation of Nanjing Vazyme Biotech Co Ltd (688105)?
The market capitalisation of Nanjing Vazyme Biotech Co Ltd is 10.6B CNY (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nanjing Vazyme Biotech Co Ltd (688105)?
The price-to-sales ratio of Nanjing Vazyme Biotech Co Ltd is 7.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nanjing Vazyme Biotech Co Ltd (688105)?
Earnings per share at Nanjing Vazyme Biotech Co Ltd are ¥−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Nanjing Vazyme Biotech Co Ltd (688105)?
The dividend yield of Nanjing Vazyme Biotech Co Ltd is 1.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Nanjing Vazyme Biotech Co Ltd (688105)?
The net margin of Nanjing Vazyme Biotech Co Ltd is −0.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nanjing Vazyme Biotech Co Ltd (688105)?
The return on equity (ROE) of Nanjing Vazyme Biotech Co Ltd is −0.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nanjing Vazyme Biotech Co Ltd (688105)?
On an EBIT basis the return on assets of Nanjing Vazyme Biotech Co Ltd is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nanjing Vazyme Biotech Co Ltd (688105)?
The operating margin of Nanjing Vazyme Biotech Co Ltd is −5.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nanjing Vazyme Biotech Co Ltd (688105)?
Revenue at Nanjing Vazyme Biotech Co Ltd is growing +18.2% versus a year earlier (3y avg −27.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nanjing Vazyme Biotech Co Ltd (688105)?
Earnings per share at Nanjing Vazyme Biotech Co Ltd are growing +325% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Nanjing Vazyme Biotech Co Ltd (688105) carry?
The net debt of Nanjing Vazyme Biotech Co Ltd is 260M CNY (fiscal year 2024, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Nanjing Vazyme Biotech Co Ltd in the live analysis
One click puts Nanjing Vazyme Biotech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 12, 2026